img

AstraZeneca provides update on tralokinumab phase III programme in uncontrolled asthma

AstraZeneca and its global biologics research and development arm, MedImmune, announced the top-line results of the phase III STRATOS 2 and TROPOS trials for tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, in severe, uncontrolled asthma. 

Sharing is caring, show love and share the thread with your friends.

Description

In STRATOS 2, tralokinumab did not achieve a statistically-significant reduction in the annual asthma exacerbation rate (AAER), the primary endpoint, in patients with severe, uncontrolled asthma and elevated levels of a biomarker, Fractional exhaled Nitric Oxide (FeNO), compared to placebo. 

In TROPOS, tralokinumab did not achieve a statistically-significant reduction in oral corticosteroid (OCS) use, the primary endpoint, when added to the standard of care, in patients dependent on OCS. 

Sean Bohen, executive vice president, Global Medicines
Development and chief medical officer, said: “The results are disappointing as we had hoped that tralokinumab would benefit patients with severe asthma, which is a complex disease with limited treatment options today.” 

FeNO is a well-established biomarker for airway inflammation and was identified in the previous pivotal trial (STRATOS 1) as most likely to predict an enhanced response to tralokinumab. 

The safety and tolerability findings in STRATOS 2 and TROPOS were consistent with those observed in previous trials with tralokinumab. 

Full data from STRATOS 1, STRATOS 2 and TROPOS will be presented at a forthcoming medical meeting.

Tags

Astrazeneca provides, tralokinumab, programme in uncontrolled asthma

References

View / Download